| Autor: |
Simon, Nicolas, Brunet, Philippe, Roumenov, Dimitri, Dussol, Bertrand, Barre, Jerome, Duche, Jean-Claude, Albengres, Edith, D'Athis, Philippe, Chauvet-Monges, Anne-Marie, Berland, Yvon, Tillement, Jean-Paul |
| Zdroj: |
British Journal of Clinical Pharmacology; Dec1997, Vol. 44 Issue 6, p591-594, 4p |
| Abstrakt: |
Aims In renal allograft recipients, trimetazidine (Vastarel® ) was proposed to be associated with the classic immunosuppressant treatments because it displays anti-ischaemic effects which may protect against cyclosporine A nephrotoxicity. The objective of this work was to assess the possibility of coadministering cyclosporin A, Sandimmun®, and trimetazidine. Methods Twelve renal transplant patients were selected on the basis of the stability of their cyclosporine A blood concentrations for the previous 3 months. They received trimetazidine, 40 mg twice daily orally for 5 days. Other coadministered drugs were kept unchanged during the study. Before and after trimetazidine administration, cyclosporine A blood concentrations, plasma interleukin-2 and soluble interleukin-2 receptor levels were measured. Results The data showed that neither cyclosporin A blood pharmacokinetic parameters, Cmax, tmax, AUC, nor the concentrations of interleukin-2 and soluble interleukin-2 receptors were significantly modified. Conclusions Therefore, it was suggested that trimetazidine may be coadministered with cyclosporine A without cyclosporine A dosage adjustment. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text